Dauer der Infektionsfähigkeit von Steinbrand (Tilletia caries)- und Zwergsteinbrandsporen (Tilletia controversa) im Boden und Stallmist unter Berücksichtigung verschiedener Fruchtfolgen in Biobetrieben

Mit Hilfe neuer Untersuchungsmethoden ist es in einem Forschungsprojekt erstmals gelungen, das Brandsporenpotential von Steinbrand (Tilletia caries)- und Zwergsteinbrand (Tilletia controversa) im Boden quantitativ zu erfassen und zu bestimmen (Dressler et al. 2011). Bei Zwergsteinbrand ist seit langem bekannt, dass neue Infektionen vom Boden aus erfolgen. Bei Steinbrand konnte dies erstmals nachgewiesen werden. Mit Feldversuchen auf Öko-Flächen, die ein hohes Sporenpotential aufweisen, soll anhand verschiedener Fruchtfolgen untersucht werden, ob unterschiedliche Bewirtschaftungen die Infektionsfähigkeit der Sporen beeinflussen. Es werden zum einen sehr gegensätzliche Bewirtschaftungen, wie offengehaltene Brache- und ständig bewachsene Kleegrasflächen durchgeführt. Zum anderen kommen praxisübliche Getreidearten und Futtererbsen zum Anbau. Mit Senf als Zwischenfrucht wird untersucht, ob Senföle einen Einfluss auf die Infektionsfähigkeit der Brandsporen haben. Zusätzlich wird festgestellt, wie sich die Sporenanzahl in befallenem Stallmist im Zeitverlauf unter Berücksichtigung der Abbauprozesse verändert

Synthesis of novel monomers containing the trifluorovinylidene group and the cyanato group and polymers thereof

Novel hybrid monomers containing both the aryltrifluorovyinyloxyether-group (TFVE-group) and the cyanato-group, their synthesis, and the synthesis of polymers made from these new hybrid monomers are disclosed

Variability of Red Supergiants in M31 from the Palomar Transient Factory

Most massive stars end their lives as Red Supergiants (RSGs), a short-lived evolution phase when they are known to pulsate with varying amplitudes. The RSG period-luminosity (PL) relation has been measured in the Milky Way, the Magellanic Clouds and M33 for about 120 stars in total. Using over 1500 epochs of R-band monitoring from the Palomar Transient Factory (PTF) survey over a five-year period, we study the variability of 255 spectroscopically cataloged RSGs in M31. We find that all RGSs brighter than M_K~ -10 mag (log(L/L_sun)>4.8) are variable at dm_R>0.05 mag. Our period analysis finds 63 with significant pulsation periods. Using the periods found and the known values of M_K for these stars, we derive the RSG PL relation in M31 and show that it is consistent with those derived earlier in other galaxies of different metallicities. We also detect, for the first time, a sequence of likely first-overtone pulsations. Comparison to stellar evolution models from MESA confirms the first overtone hypothesis and indicates that the variable stars in this sample have 12 M_sun<M<24 M_sun. As these RSGs are the immediate progenitors to Type II-P core-collapse supernovae (SNe), we also explore the implication of their variability in the initial-mass estimates for SN progenitors based on archival images of the progenitors. We find that this effect is small compared to the present measurement errors.Comment: 17 pages, 10 figure

Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

Dick Menzies and colleagues report findings from a collaborative, individual patient-level meta-analysis of treatment outcomes among patients with multidrug-resistant tuberculosis. Background: Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study

<p>Abstract</p> <p>Background</p> <p>The aim of this study was to investigate the efficacy and safety of oxaliplatin ± gemcitabine in patients with diffuse malignant pleural mesothelioma (MPM) pretreated with pemetrexed.</p> <p>Methods</p> <p>The study enrolled consecutive patients with relapsed MPM, all of them pretreated with a platin-pemetrexed-based chemotherapy. Oxaliplatin 80 mg/m²was administered as monotherapy or in combination with gemcitabine 1000 mg/m²given on day 1 and 8. Cycles were repeated every 21 days. The primary endpoints were response rate and disease control rate. Secondary endpoints included overall survival (OS), time to tumour progression (TTP), progression-free survival (PFS), time to treatment failure (TTF), and toxicity.</p> <p>Results</p> <p>Between February 2005 and September 2007 29 patients (median age: 65.0 years, World Health Organisation (WHO) performance status: 0–3) were enrolled. The follow-up period encompassed 5.4 to 97.4 weeks (median: 24.3 weeks). Out of these 29 patients, 15 were treated in second, 10 in third, 3 in fourth and 1 in fifth line, respectively. The majority of the patients received the combination oxaliplatin and gemcitabine (n = 25 vs. 4; 86.2 vs. 13.8%).</p> <p>The median overall survival (OS) was 71.7 weeks (30.6–243.3 weeks), whereas survival from the start of oxaliplatin/gemcitabine-treatment was 24.3 weeks (5.4–97.3 weeks). Median time to tumour progression (TTP) was 9.3 weeks (3.0–67.6 weeks).</p> <p>Partial response (PR) was observed in 2 patients (6.9%), stable disease (SD) for at least three courses of treatment in 11 patients (37.9%). Thus, disease control rate was 44.8%, whereas 16 of 29 patients exhibited progressive disease (55.2%).</p> <p>The toxicity profile was favourable, with no WHO grade 4-toxicities, only few dose-reductions were performed due to non-symptomatic haematotoxicities (neutropenia, thrombopenia). Mild WHO grade 2 neurotoxicity was seen in 6 patients.</p> <p>Conclusion</p> <p>Pemetrexed-pretreated patients with progressive MPM may benefit from a consecutive chemotherapy with oxaliplatin and gemcitabine without significant toxicity.</p

Complement activation by in vivo neonatal and in vitro extracorporeal membrane oxygenation.

Complment activation during extracorporeal membrane oxygenation (ECMO) in newborns can be caused by both the underlying disease processes and by blood contact with the ECMO circuit. We investigated the relative importance of these mechanisms by measuring C3a, C5a and sC5b-9 before, during and after neonatal ECMO in six consecutive newborn patients using enzyme-linked immunoassay. In addition complement activation during in vitro ECMO with repeated flow of the same blood volume was measured using blood from healthy adult donors. C3a increased significantly in vivo after 1 h (from 1035+/-193 to 1865+/-419 microg/l) and in vitro ECMO (from 314+/-75 to 1962+/-1062 microg/l). C5a increased during ECMO without significant differences between in vivo and in vitro activation. In neonatal patients, sC5b-9 rose faster than in vitro, but the rapid increase was also significant for in vitro experiments (in vivo: from 328+/-63 to 1623+/-387 microg/l after 2 h; and in vitro: from 78+/-32 to 453+/-179 microg/l after 8 h). After this initial peak at 1-2 h, complement activation decreased gradually until 2-3 days after the initiation of ECMO. We conclude that in newborns the rapid activation of the complement system after the start of ECMO is predominantly caused by contact with artificial surfaces rather than the patient's underlying disease

Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats

BACKGROUND: Neuromyelitis optica (NMO) is a severe, disabling disease of the central nervous system (CNS) characterized by the formation of astrocyte-destructive, neutrophil-dominated inflammatory lesions in the spinal cord and optic nerves. These lesions are initiated by the binding of pathogenic aquaporin 4 (AQP4)-specific autoantibodies to astrocytes and subsequent complement-mediated lysis of these cells. Typically, these lesions form in a setting of CNS inflammation, where the blood–brain barrier is open for the entry of antibodies and complement. However, it remained unclear to which extent pro-inflammatory cytokines and chemokines contribute to the formation of NMO lesions. To specifically address this question, we injected the cytokines interleukin-1 beta, tumor necrosis factor alpha, interleukin-6, interferon gamma and the chemokine CXCL2 into the striatum of NMO-IgG seropositive rats and analyzed the tissue 24 hours later by immunohistochemistry. RESULTS: All injected cytokines and chemokines led to profound leakage of immunoglobulins into the injected hemisphere, but only interleukin-1 beta induced the formation of perivascular, neutrophil-infiltrated lesions with AQP4 loss and complement-mediated astrocyte destruction distant from the needle tract. Treatment of rat brain endothelial cells with interleukin-1 beta, but not with any other cytokine or chemokine applied at the same concentration and over the same period of time, caused profound upregulation of granulocyte-recruiting and supporting molecules. Injection of interleukin-1 beta caused higher numbers of blood vessels with perivascular, cellular C1q reactivity than any other cytokine tested. Finally, the screening of a large sample of CNS lesions from NMO and multiple sclerosis patients revealed large numbers of interleukin-1 beta-reactive macrophages/activated microglial cells in active NMO lesions but not in MS lesions with comparable lesion activity and location. CONCLUSIONS: Our data strongly suggest that interleukin-1 beta released in NMO lesions and interleukin-1 beta-induced production/accumulation of complement factors (like C1q) facilitate neutrophil entry and BBB breakdown in the vicinity of NMO lesions, and might thus be an important secondary factor for lesion formation, possibly by paving the ground for rapid lesion growth and amplified immune cell recruitment to this site